盐酸表柔比星联合卡培他滨片治疗三阴性乳腺癌的临床疗效及对血清相关指标水平变化

Clinical Curative Effect of Epirubicin Hydrochloride Combined with Capecitabine Tablets in Treatment of Triple Negative Breast Cancer and Effect on the Changes of Level of Serum Related Indicators

目的比较三阴性乳腺癌患者应用盐酸表柔比星和卡培他滨片联合治疗的临床疗效和对血清相关指标水平的影响。方法分析该院于2016年12月—2017年12月收治的96例三阴性乳腺癌患者资料,按照不同治疗方案分成两组,将行盐酸表柔比星单纯治疗48例患者作为对照组,将和卡培他滨片联合治疗48例患者作为观察组,比较两组临床疗效和血清相关指标水平。结果观察组总有效率83.33%比对照组45.83%高,且血管内皮生长因子-C、血清骨桥蛋白水平(5.11±0.04)μg/mL、(580.40±71.06)pg/mL均比对照组优(P<0.05);观察组总不良反应率8.33%比对照组25.00%低(P<0.05)。结论三阴性乳腺癌患者应用盐酸表柔比星和卡培他滨片联合治疗能够改善临床症状,优化血清指标,且安全性较高,具较高推广价值。

Objective To compare the curative effect of epirubicin hydrochloride combined with capecitabine tablets in treatment of triple negative breast cancer and effect on the changes of level of serum related indicators.Methods 96 cases of patients with triple negative breast cancer admitted and treated in our hospital from December 2016 to December 2017 were selected and divided into two groups according to different treatment plans,with 48 cases in each,the control group were treated with single capecitabine tablets,while the observation group were treated with epirubicin hydrochloride combined with capecitabine tablets,and the clinical curative effect and serum related indicators were compared between the two groups.Results The total effective rate in the observation group was higher than that in the control group(83.33%vs 45.83%),and the vascular endothelial growth factor-C and serum osteopontin in the observation group were respectively(5.11±0.04)μg/L,(580.40±71.06)pg/mL,which were better than those in the control group(P<0.05),and the total adverse reaction rate in the observation group was lower than that in the control group(8.33%vs 25.00%)(P<0.05).Conclusion The epirubicin hydrochloride combined with capecitabine tablets in treatment of triple negative breast cancer can improve the clinical symptoms,and optimize the serum indicators,with high safety,which is of higher promotion value.